TRML241220P40000
- 0.00
- 0.000.00%
Tourmaline Bio Newsroom
Leerink Partners Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Strategic Developments in Tourmaline Bio's Cardiovascular Programs Drive Buy Rating
Tourmaline Bio Unveils Clinical Progress and New Indication
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
UBS Raises Price Target on Tourmaline Bio to CA$73 From CA$70, Maintains Neutral Rating
Tourmaline Bio Initiated at Outperform by BMO Capital
Tourmaline Bio Price Target Announced at $50.00/Share by BMO Capital
Tourmaline Bio Analyst Ratings
BMO Capital Initiates Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $50
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Express News | Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing
Talaris Therapeutics GAAP EPS of -$0.78 Beats by $0.05
Tourmaline Bio | 10-Q: Q3 2024 Earnings Report
Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027
Tourmaline Bio | 8-K: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio 3Q Loss/Shr 78c >TRML